Recovery · Investigational
DSIP (Delta Sleep-Inducing Peptide)
No lawful US pathway
01 · Overview
A nonapeptide (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) first isolated in 1977 from the cerebral venous blood of sleeping rabbits and initially proposed as a sleep-promoting factor. Its gene, precursor protein and receptor have never been identified, and a 2006 review concluded that the evidence for DSIP as a sleep factor remains weak and its mechanism unresolved (PMID 16539679).
Rat studies suggest stress-protective effects, including preserved brain mitochondrial respiration under hypoxia (PMID 12668217).
02 · Research summary & key findings
In a small double-blind trial in 16 chronic insomniacs, DSIP produced only weak improvements in sleep efficiency and latency and no change in subjective sleep quality; the authors judged it unlikely to be of major benefit (PMID 1299794). Other clinical evidence is mostly old case reports (PMID 3582201), and its sleep-promoting role remains unproven (PMID 16539679).
03 · Regulatory status
DSIP (Delta Sleep-Inducing Peptide) is in the investigational stage. While preclinical and early-phase data exist, it has not received regulatory approval for clinical use in the United States.
No lawful pathway today
DSIP (Delta Sleep-Inducing Peptide) is not FDA-approved and does not currently have a lawful prescription or compounding pathway in the United States, so we do not sell it and will not book a consultation for it. That can change: in 2026 FDA began reviewing several peptides for compounding. If you are working on the goal it is studied for, a licensed clinician can tell you what is lawfully available, which may be something else.
See the 3 FDA-approved compounds in Recovery
Tell me if the status changes
One email, only if this compound's regulatory standing actually moves. Not a newsletter, not a sales sequence.
Looking for a lawful, clinician-prescribed option for injury recovery and tissue repair?
DSIP (Delta Sleep-Inducing Peptide) is an investigational compound, is not FDA-approved, and has no lawful US compounding pathway, so we do not offer it and no clinician we work with will prescribe it. Products sold online as “research chemicals” are not made or tested to the standards required of medicines. If you are working on injury recovery and tissue repair, a licensed clinician can tell you at a free consultation whether an FDA-approved or lawfully compounded treatment fits you, or whether nothing does.
Explore lawful options (free intake)About 3 minutes. If a protocol is prescribed through our provider, we earn 10% of the sale. See the receipts.
04 · Administration routes
- Subcutaneous injection
- Intravenous
- Intranasal
References
- [1]Delta sleep inducing peptide (DSIP): effect on respiration activity in rat brain mitochondria and stress protective potency under experimental hypoxia Peptides, 2003. PMID 12668217
- [2]Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients. A double-blind study Neuropsychobiology, 1992. PMID 1299794
- [3]Delta sleep-inducing peptide (DSIP): a still unresolved riddle J Neurochem, 2006. PMID 16539679
- [4][The use of DSIP (delta sleep-inducing peptide) in the correction of phase-shifted insomnia] Dtsch Med Wochenschr, 1987. PMID 3582201
Primary literature
- PubMed: "DSIP"
Peer-reviewed literature indexed by the National Library of Medicine.
- ClinicalTrials.gov: "DSIP"
Registered interventional and observational studies, including status and phase.
- PubChem: "DSIP"
Chemical structure, molecular properties, and bioactivity data.
Related peptides in Recovery
Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed. Clinicians: join the network.